Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, Fidenza, Italy, v. 38, n. 3, p. e2021035, 2021. DOI: 10.36141/svdld.v38i3.11684. Disponível em: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/11684.. Acesso em: 30 jun. 2024.